You are here

Article Text

Article menu
Download PDFPDF
Viewpoint
Drug eluting stents: maximising benefit and minimising cost
  1. J Gunn1,
  2. A C Morton1,
  3. C Wales1,
  4. C M H Newman1,
  5. D C Crossman1,
  6. D C Cumberland2
  1. 1Cardiovascular Research Group, Division of Clinical Sciences (Northern General Hospital), University of Sheffield, Sheffield, UK
  2. 2Ampang Puteri Specialist Hospital, Jalang Memanda, Mukin Ampang, Selangor, Malaysia
  1. Dr Julian Gunn, Cardiovascular Research Group, Division of Clinical Sciences (Northern General Hospital), University of Sheffield, Clinical Sciences Building, Northern General Hospital, Sheffield, S5 7AU, UK;
    J.Gunn{at}Sheffield.ac.uk

Abstract

A policy of selective implantation of drug eluting stents, in a minority of lesions most likely to benefit, seems to be a rational way to employ this new and currently costly technology

  • drug eluting stents
  • sirolimus
  • percutaneous coronary intervention
  • restenosis
  • CABG, coronary artery bypass grafting
  • IVUS, intravascular ultrasound
  • MLD, minimum lumen diameter
  • PCI, percutaneous coronary intervention
  • RAVEL, randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization
  • SIRIUS, US multicenter, randomized, double-blind study of the sirolimus-eluting stent in de novo coronary lesions
  • TLR, target lesion revascularisation
  • TVF, target vessel failure

https://doi.org/10.1136/heart.89.2.127

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text